Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IGM Biosciences, Inc.

Get SEC filing alerts via email and in your feed for IGM Biosciences, Inc.

IGMS

IGM Biosciences, Inc.

About IGM Biosciences, Inc.

IGM Biosciences is a biotechnology company specializing in the development of IgM antibodies for autoimmune and inflammatory diseases. Its platform leverages unique antibody engineering technologies, with key collaborations including Sanofi. The company focuses on innovative biologics, patent-protected platforms, and antibody manufacturing, targeting global markets. Its core value lies in creating potent, multimeric antibody therapies with potential advantages over traditional IgG-based treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from IGM Biosciences, Inc.

1
1
IGM Biosciences, Inc. IGM Biosciences Reports $143.6M Revenue Surge and $97.6M Net Income in Latest Quarter

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
IGM Biosciences, Inc. IGM Biosciences Reports $52.9 Million Net Loss in Q1 2025 Amid Restructuring Efforts

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
IGM Biosciences, Inc. IGM Biosciences Reports $195.8 Million Net Loss for 2024, Focuses on Immunology

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
IGM Biosciences, Inc. IGM Biosciences Reports Decline in Assets, Net Loss, and Restructuring Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments